-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
*Only for medical professionals to read the norms, precision and care, the 5th Eli Lilly China Gastrointestinal Tumor Summit Forum will be grandly opened on July 31
.
In the early stage of the conference, the "medical community" had the honor to interview Professor Shen Lin from Peking University Cancer Hospital, and asked her to talk about the current situation and development of precision treatment of digestive tumors, and to draw up a blueprint for the field
.
Professor Shen Lin’s wonderful video explores the mechanism of action and seeks to develop precision treatment for digestive tumors | Professor Shen Lin: Relatively speaking, gastrointestinal tumors are relatively familiar tumors, including colorectal cancer, esophageal cancer, and gastric cancer
.
Among them, upper gastrointestinal tumors (gastric/esophageal cancer) are relatively common, idiopathic, and high-incidence tumors in China, but bowel cancer is a high-incidence tumor in the world including China, especially in large and medium-sized cities.
In recent years, bowel cancer The incidence rate is increasing year by year, and the incidence rate in big cities such as Shanghai and Beijing ranks among the top 2[1]
.
It can be said that gastrointestinal tumors have become a clinically very concerned and urgent treatment problem
.
In recent years, immunotherapy has made rapid progress in the field of solid tumors
.
In the field of colorectal cancer, immunotherapy seems to be in a leading position in the world, but at the same time it seems to be relatively lagging in the development of a wide range of populations
.
The reason behind this seemingly contradictory status quo is this: the efficacy of immunotherapy is evaluated in multiple dimensions such as biomarkers, and the field of bowel cancer is at the forefront in this direction
.
PD-1/PD-L1 inhibitor immunotherapy currently has a good effect on MSI-H patients, and it has developed from end-line therapy to the standard of first-line therapy
.
However, the efficacy of immunotherapy has not been seen in MSS colorectal cancer patients, but we were pleasantly surprised to find in our preliminary research that anti-angiogenesis therapy combined with immunotherapy can produce a certain synergistic therapeutic effect on microsatellite stable (MSS) colorectal cancer.
This allows us to further understand the role of anti-angiogenesis therapy in colorectal cancer
.
At present, first-line bevacizumab, third-line, and third-line and above anti-angiogenic TKIs in colorectal cancer, including fruquintinib, regorafenib, etc.
, have achieved good results, and evidence-based medical evidence has shown that these drugs are either Monotherapy or in combination with other drugs can bring significant benefits to patients with colorectal cancer
.
In addition, I personally believe that the development direction of gastrointestinal tumor treatment has two lines: First, the whole-process management is selected based on the understanding of the immune microenvironment of colorectal cancer
.
With the deepening of research, we will further understand the impact of immunotherapy and anti-angiogenesis on the tumor immune microenvironment
.
The second is precision treatment based on Biomarker
.
With the deepening of the understanding of the disease, we have gradually realized the changes in precision treatment brought about by the difference of the real target population
.
For example, the efficacy of EGFR monoclonal antibody in RAS wild-type colorectal cancer, the response of people with BRAF mutations, HER2 positive, POLE mutations, and TMB-H to PD-1/PD-L1 monoclonal antibodies, and even rare populations such as NTRK.
Response to immunotherapy
.
Therefore, with the further extension and exploration of colorectal cancer immunity and anti-angiogenesis therapy, it will bring more survival benefits and survival hopes to colorectal cancer patients
.
New drug research and development has promoted the precise development of gastrointestinal tumors | Professor Lin Shen: Precise targeted therapy for colorectal cancer is bound to be its future development direction
.
We have seen that people with a mutation rate of less than 5% in such colon cancers as HER2, c-MET, BRAF to KRASG12C and NTRK, people with an incidence of about 5% such as MSI-H [2] and all RAS mutations For the population, its therapeutic breakthroughs all await the research and development of new drugs
.
At present, many related researches are being carried out in the field, and new drugs are being developed.
I believe that more and more products and clinical studies will be presented to you in the field of precision targeted therapy for colorectal cancer
.
Driven by responsibility to promote a new pattern of precision treatment of digestive tumors | Professor Lin Shen: Eli Lilly has always focused on the development of the field of digestive tumors
.
From the current Fruquintinib in the third-line and above treatment of colorectal cancer, to the highly anticipated clinical research of Ramucirumab (Ramucirumab) in the second-line treatment of gastric cancer is about to land, and cooperation with other companies in the field The research and development of PD-1 related products fully demonstrates Eli Lilly's attention to gastrointestinal tumors
.
Eli Lilly has never slowed down whether it is in the study of the mechanism of anti-angiogenic drugs on the immune microenvironment or in precision targeted therapy
.
In fact, even if it is less than 1% of the patient population of a certain tumor type, as long as the effect of a certain target drug is very good, every company, every product, and every researcher will not ignore this part of the population
.
Therefore, I feel that precision therapy has entered the stage of individualized research based on the needs of patients
.
I believe that Eli Lilly will also present leading clinical research in this area to everyone, and I personally look forward to it! Expert profile Professor Lin Shen, Deputy Dean of Peking University Cancer Hospital, Peking University Cancer Hospital, Director of the Department of Digestive Oncology and Phase I Clinical Ward, Chief Physician, Doctoral Supervisor, Chinese Physician, Chinese Physician Chairman of the MDT Special Committee of the Association of Surgeons, Secretary-General of the Gastric Cancer Special Committee of the Chinese Anti-Cancer Association, Deputy Chairman of the Colorectal Cancer Special Committee, Deputy Leader of the Gastroenterology Group of the Oncology Branch of the Chinese Medical Association, Deputy Leader of the Colorectal Group CSCO References: [1] Analysis of the prevalence of malignant tumors in China in 2015, Chinese Journal of Oncology, Volume 41, Issue 1, 2019 [2] Ooki A, Shinozaki E, Yamaguchi K.
Immunotherapy in Colorectal Cancer: Current and Future Strategies.
J Anus Rectum Colon.
2021 Jan 28;5(1):11-24.
doi: 10.
23922/jarc.
2020-064.
PMID: 33537496; PMCID: PMC7843143.
PP-ON-CN-0730*This article is only used to provide scientific information to medical professionals and does not represent the views of this platform
.
In the early stage of the conference, the "medical community" had the honor to interview Professor Shen Lin from Peking University Cancer Hospital, and asked her to talk about the current situation and development of precision treatment of digestive tumors, and to draw up a blueprint for the field
.
Professor Shen Lin’s wonderful video explores the mechanism of action and seeks to develop precision treatment for digestive tumors | Professor Shen Lin: Relatively speaking, gastrointestinal tumors are relatively familiar tumors, including colorectal cancer, esophageal cancer, and gastric cancer
.
Among them, upper gastrointestinal tumors (gastric/esophageal cancer) are relatively common, idiopathic, and high-incidence tumors in China, but bowel cancer is a high-incidence tumor in the world including China, especially in large and medium-sized cities.
In recent years, bowel cancer The incidence rate is increasing year by year, and the incidence rate in big cities such as Shanghai and Beijing ranks among the top 2[1]
.
It can be said that gastrointestinal tumors have become a clinically very concerned and urgent treatment problem
.
In recent years, immunotherapy has made rapid progress in the field of solid tumors
.
In the field of colorectal cancer, immunotherapy seems to be in a leading position in the world, but at the same time it seems to be relatively lagging in the development of a wide range of populations
.
The reason behind this seemingly contradictory status quo is this: the efficacy of immunotherapy is evaluated in multiple dimensions such as biomarkers, and the field of bowel cancer is at the forefront in this direction
.
PD-1/PD-L1 inhibitor immunotherapy currently has a good effect on MSI-H patients, and it has developed from end-line therapy to the standard of first-line therapy
.
However, the efficacy of immunotherapy has not been seen in MSS colorectal cancer patients, but we were pleasantly surprised to find in our preliminary research that anti-angiogenesis therapy combined with immunotherapy can produce a certain synergistic therapeutic effect on microsatellite stable (MSS) colorectal cancer.
This allows us to further understand the role of anti-angiogenesis therapy in colorectal cancer
.
At present, first-line bevacizumab, third-line, and third-line and above anti-angiogenic TKIs in colorectal cancer, including fruquintinib, regorafenib, etc.
, have achieved good results, and evidence-based medical evidence has shown that these drugs are either Monotherapy or in combination with other drugs can bring significant benefits to patients with colorectal cancer
.
In addition, I personally believe that the development direction of gastrointestinal tumor treatment has two lines: First, the whole-process management is selected based on the understanding of the immune microenvironment of colorectal cancer
.
With the deepening of research, we will further understand the impact of immunotherapy and anti-angiogenesis on the tumor immune microenvironment
.
The second is precision treatment based on Biomarker
.
With the deepening of the understanding of the disease, we have gradually realized the changes in precision treatment brought about by the difference of the real target population
.
For example, the efficacy of EGFR monoclonal antibody in RAS wild-type colorectal cancer, the response of people with BRAF mutations, HER2 positive, POLE mutations, and TMB-H to PD-1/PD-L1 monoclonal antibodies, and even rare populations such as NTRK.
Response to immunotherapy
.
Therefore, with the further extension and exploration of colorectal cancer immunity and anti-angiogenesis therapy, it will bring more survival benefits and survival hopes to colorectal cancer patients
.
New drug research and development has promoted the precise development of gastrointestinal tumors | Professor Lin Shen: Precise targeted therapy for colorectal cancer is bound to be its future development direction
.
We have seen that people with a mutation rate of less than 5% in such colon cancers as HER2, c-MET, BRAF to KRASG12C and NTRK, people with an incidence of about 5% such as MSI-H [2] and all RAS mutations For the population, its therapeutic breakthroughs all await the research and development of new drugs
.
At present, many related researches are being carried out in the field, and new drugs are being developed.
I believe that more and more products and clinical studies will be presented to you in the field of precision targeted therapy for colorectal cancer
.
Driven by responsibility to promote a new pattern of precision treatment of digestive tumors | Professor Lin Shen: Eli Lilly has always focused on the development of the field of digestive tumors
.
From the current Fruquintinib in the third-line and above treatment of colorectal cancer, to the highly anticipated clinical research of Ramucirumab (Ramucirumab) in the second-line treatment of gastric cancer is about to land, and cooperation with other companies in the field The research and development of PD-1 related products fully demonstrates Eli Lilly's attention to gastrointestinal tumors
.
Eli Lilly has never slowed down whether it is in the study of the mechanism of anti-angiogenic drugs on the immune microenvironment or in precision targeted therapy
.
In fact, even if it is less than 1% of the patient population of a certain tumor type, as long as the effect of a certain target drug is very good, every company, every product, and every researcher will not ignore this part of the population
.
Therefore, I feel that precision therapy has entered the stage of individualized research based on the needs of patients
.
I believe that Eli Lilly will also present leading clinical research in this area to everyone, and I personally look forward to it! Expert profile Professor Lin Shen, Deputy Dean of Peking University Cancer Hospital, Peking University Cancer Hospital, Director of the Department of Digestive Oncology and Phase I Clinical Ward, Chief Physician, Doctoral Supervisor, Chinese Physician, Chinese Physician Chairman of the MDT Special Committee of the Association of Surgeons, Secretary-General of the Gastric Cancer Special Committee of the Chinese Anti-Cancer Association, Deputy Chairman of the Colorectal Cancer Special Committee, Deputy Leader of the Gastroenterology Group of the Oncology Branch of the Chinese Medical Association, Deputy Leader of the Colorectal Group CSCO References: [1] Analysis of the prevalence of malignant tumors in China in 2015, Chinese Journal of Oncology, Volume 41, Issue 1, 2019 [2] Ooki A, Shinozaki E, Yamaguchi K.
Immunotherapy in Colorectal Cancer: Current and Future Strategies.
J Anus Rectum Colon.
2021 Jan 28;5(1):11-24.
doi: 10.
23922/jarc.
2020-064.
PMID: 33537496; PMCID: PMC7843143.
PP-ON-CN-0730*This article is only used to provide scientific information to medical professionals and does not represent the views of this platform
